PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1399-1405

  Panebianco, Valeria ^a   Sciarra, Alessandro ^a   De Berardinis, Ettore ^a   Busetto, Gian Maria ^a   Lisi, Danilo ^a   Buonocore, Valeria ^a   Gentile, Vincenzo ^a   Di Silverio, Franco ^a   Passariello, Roberto ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

DCEMR; MRSI; PCA3 urinary test; Prostate cancer

Indexed keywords

PROSTATE ANTIGEN; PROSTATE ANTIGEN 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIGITAL RECTAL EXAMINATION; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; ADULT; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CONTRAST MEDIA; DIGITAL RECTAL EXAMINATION; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 79956116943     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Draisma G, Boer R, Otto SJ et al: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868, 2003.
2. Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, Adami HO et al: Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99: 526-532, 2007. (Pubitemid 47073555)
3. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al: Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
4. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs WB: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59(23): 5975-5979, 1999. (Pubitemid 30004960)
5. Hessels D, Klein Gunnewiek JM, van Oort I et al: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-15; discussion 15-6, 2003.
6. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Masse B, Piche L and Chypre C: uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64: 311-315; discussion 315-316, 2004.
7. Tinzl M, Marberger M, Horvath S and Chypre C: DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 46: 182-186, 2004. (Pubitemid 38902733)
8. de Kok JB, Verhaegh GW, Roelofs RW et al: DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698, 2002. (Pubitemid 34462754)
9. Rajesh A, Coakley FV and Khrhanewicz J: 3D spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol 62: 921-929, 2007. (Pubitemid 47317139)
10. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Bernardo S, Passariello R and Gentile V: Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 16(6): 1875-1883, 2010.
11. Villeirs GM, Oosterlinck W, Vanherreweghe E and De Meerleer GO: A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur J Radiol 73(2): 352-356, 2010.
12. de la Rosette JJ, Wink MH, Mamoulakis C, Wondergem N, ten Kate FJ, Zwinderman K, de Reijke TM and Wijkstra H: Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol. J Urol 182(4): 1329-1336, 2009.
13. Scattoni V, Raber M, Abdollah F, Roscigno M, Dehò F, Angiolilli D, Maccagnano C, Gallina A, Capitanio U, Freschi M, Doglioni C, Rigatti P and Montorsi F: Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 57(1): 1-8, 2010.
14. Sciarra A, Autran Gomez A, Salciccia S et al: Biopsy-derived Gleason artifact and prostate volume: experience using ten samples in larger prostates. Urol Int 80: 145-150, 2008. (Pubitemid 351440507)
15. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS and Rittenhouse H: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095, 2006. (Pubitemid 43794421)
16. Sciarra A, Panebianco V and Salciccia S: Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54: 589-600, 2008.
17. Rajesh A and Coakley FV: MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin N Am 12: 557-579, 2004.
18. Sciarra A, Salciccia S and Panebianco V: Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: a modern approach in prostate cancer imaging. Eur Urol 54: 485-488, 2008.
19. Mueller-Lisse UG and Scherr MK: Proton MR spectroscopy of the prostate. Eur J Radiol 63(3): 351-360, 2007.
20. Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, Wood DP Jr and Pontes JE: Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate 39: 60-66, 1999. (Pubitemid 29143111)
21. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, Pontes JE and Wood DP Jr.: Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 53: 372-377, 1999.
22. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M and Haese A: Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59(1): 96-105, 2010.
23. Fütterer JJ, Heijmink SW, Scheenen TW et al: Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241: 449-458, 2006. (Pubitemid 44632891)
24. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Fütterer JJ and Barentsz JO: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 183(2): 527-528, 2010.
25. Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, Lau WK, Ng WS and Cheng CW: Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171(4): 1482-1486, 2004. (Pubitemid 38365401)
26. Hricak H: MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 78: 103-111, 2005.
27. Fütterer JJ, Scheenen TW, Heijmink SW et al: Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 42: 116-122, 2007. (Pubitemid 46104892)
28. Fütterer JJ, Shukla-Dave A, Hricak H, Moskowitz C et al: Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 245: 499-506, 2007. (Pubitemid 47612532)
29. Popa I, Fradet Y, Beaudry G, Hovington H, Beaudry G and Tetu B: Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 20: 1121-1127, 2007. (Pubitemid 47609070)
30. Deras IL, Aubin SM, Blase A et al: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587-1592, 2008.
31. Yakar D, Hambrock T, Huisman H, Hulsbergen-van de Kaa CA, van Lin E, Vergunst H, Hoeks CM, van Oort IM, Witjes JA, Barentsz JO and Fütterer JJ: Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol 45(3): 121-125, 2010.